Literature DB >> 8917705

Cell cycle alterations associated with covalent binding of monocrotaline pyrrole to pulmonary artery endothelial cell DNA.

H C Thomas1, M W Lamé, D W Wilson, H J Segall.   

Abstract

In the monocrotaline (MCT) rat model of pulmonary hypertension, the pulmonary vascular endothelium is thought to be the early target of the bifunctionally reactive metabolite monocrotaline pyrrole (MCTP). In previous studies, bovine pulmonary arterial endothelial cells (BPAEC) exposed to MCTP exhibited inhibition of proliferation. Since other compounds that crosslink DNA lead to cell cycle alterations, we utilized BPAEC to correlate the effects of MCTP on the cell cycle with the extent of covalent binding of [14C]MCTP to BPAEC DNA. Dose response (0.0 to 50.0 micrograms MCTP/ ml) and 96-hr time course (5 micrograms MCTP/ml low dose or 34.5 micrograms MCTP/ml high dose) studies were carried out followed by flow cytometric cell cycle analysis. High concentrations of MCTP caused cell cycle arrest in S phase, beginning by 24 hr, while an S phase delay was observed at low concentrations, but progressed to a G2 + M phase arrest by 48 hr. Covalent DNA binding (34.5 micrograms/ml of [14C]MCTP incubated with BPAEC) occurred within 1 hr and progressively increased through 96 hr. In conclusion, covalent binding of MCTP to DNA is associated with cell cycle arrest; however, the position of cell cycle arrest is dependent on dose, with an S phase arrest at high concentrations and a G2 + M phase arrest at low concentrations of MCTP. The mechanism by which MCTP induces proliferative inhibition could be cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917705     DOI: 10.1006/taap.1996.0289

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

1.  Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells.

Authors:  M Ramos; M W Lamé; H J Segall; D W Wilson
Journal:  Vascul Pharmacol       Date:  2007-02-02       Impact factor: 5.773

2.  Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging.

Authors:  Jason Lee; Reuben Reich; Fang Xu; Pravin B Sehgal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-31       Impact factor: 5.464

Review 3.  Reactive oxygen species in pulmonary vascular remodeling.

Authors:  Saurabh Aggarwal; Christine M Gross; Shruti Sharma; Jeffrey R Fineman; Stephen M Black
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

4.  Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats.

Authors:  Daniel J Lachant; David F Meoli; Deborah Haight; Jason A Lyons; Robert F Swarthout; R James White
Journal:  Exp Lung Res       Date:  2018-01-30       Impact factor: 2.459

5.  The Role of Astrocytes in Metabolism and Neurotoxicity of the Pyrrolizidine Alkaloid Monocrotaline, the Main Toxin of Crotalaria retusa.

Authors:  Bruno Penas Seara Pitanga; Ravena P Nascimento; Victor Diógenes A Silva; Silvia L Costa
Journal:  Front Pharmacol       Date:  2012-08-03       Impact factor: 5.810

6.  Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension.

Authors:  Jing Luo; Haiyan Li; Zhenwei Liu; Chenlu Li; Ruochen Wang; Jinxia Fang; Saisai Lu; Jing Guo; Xiaochun Zhu; Xiaobing Wang
Journal:  BMC Med Genomics       Date:  2020-06-26       Impact factor: 3.063

7.  Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry.

Authors:  Klaus Braun; Manfred Wiessler; Volker Ehemann; Ruediger Pipkorn; Herbert Spring; Juergen Debus; Bernd Didinger; Mario Koch; Gabriele Muller; Waldemar Waldeck
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

8.  A process-based review of mouse models of pulmonary hypertension.

Authors:  Mita Das; Joshua Fessel; Haiyang Tang; James West
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

9.  TMZ-BioShuttle--a reformulated temozolomide.

Authors:  Waldemar Waldeck; Manfred Wiessler; Volker Ehemann; Ruediger Pipkorn; Herbert Spring; Juergen Debus; Bernd Didinger; Gabriele Mueller; Joerg Langowski; Klaus Braun
Journal:  Int J Med Sci       Date:  2008-09-15       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.